RLLVF:OTC-Relevium Technologies Inc (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC

Last Closing Price

USD 0.01

Change

0.00 (0.00)%

Market Cap

USD 2.07M

Volume

5.00K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Relevium Technologies Inc. engages in the identification, evaluation, acquisition, and operation of brands and businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and cosmeceuticals primarily through its Bioganix brand portfolio online; dietary supplements under the LeefyLyfe brand name; and skin care products under the Push & Pull System brand. It also provides Relevium Senior, a geriatric brand targeting inflammatory conditions, including joints, heart, and brain; and Relevium Kids, a pediatric brand of nutraceuticals and oral nutritional supplements. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. Relevium Technologies Inc. is headquartered in Montreal, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALBHF Alibaba Health Information Tec..

N/A

USD29.27B 542.50 70.16
RADLY Raia Drogasil S.A

N/A

USD8.89B 84.14 4.34
CLCGY Clicks Group Limited

N/A

USD4.83B 34.98 1.11
ZRSEF Zur Rose Group AG

N/A

USD4.09B N/A N/A
SDGCF Sundrug Co.,Ltd

N/A

USD3.81B 16.60 0.08
FFLWF Fire & Flower Holdings Corp

N/A

USD0.29B N/A 11.91
DRVD Driven Deliveries, Inc

N/A

USD0.06B N/A N/A
RXMD Progressive Care, Inc

N/A

USD0.03B N/A 17.28
HADV Health Advance Inc

N/A

USD0.01B N/A N/A
HEWA HealthWarehouse.com, Inc

N/A

USD8.78M 56.67 N/A

ETFs Containing RLLVF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Pharmaceutical Retailers)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -62.50% 6% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.50% 6% F 2% F
Trailing 12 Months  
Capital Gain -65.71% 13% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.71% 13% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.13% 6% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.13% 6% F 4% F
Risk Return Profile  
Volatility (Standard Deviation) 57.44% 88% B+ 45% F
Risk Adjusted Return -42.01% 6% F 11% F
Market Capitalization 2.07M 47% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Pharmaceutical Retailers)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 233.67 11% F 2% F
Price / Cash Flow Ratio -0.96 75% C 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -426.47% 20% F 4% F
Return on Invested Capital -50.99% 20% F 12% F
Return on Assets -9.97% 46% F 32% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.43 24% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector